Amrutanjan Health Care Limited

rs,

, Bandra (E) Mumbai 400 051 BSE Limited Department of Corporate Services l51 Floor, P.J . Towers, Dalal Street, Mumbai 400 001 Symbol: AMRUTANJAN Scrip Code: 590006 Dear Sir/ Madam, Sub: Su

15%

n Trade, and E-Com channels which have shown growth in Q1. Q1 of the year usually produces around 15% of annual sales with a lesser absorption of fixed costs. The bottom line of Q1FY23 was hit owing t

Rs.13.53 crore

ulted in a big swing in profits. The micro picture: Head category: 1. We have lost revenue of Rs.13.53 crores in Q1 FY23 which is a drop over Q1FY22 by 25.66% but higher than Q1FY21 revenue by 18.91%. 2.

25.66%

ad category: 1. We have lost revenue of Rs.13.53 crores in Q1 FY23 which is a drop over Q1FY22 by 25.66% but higher than Q1FY21 revenue by 18.91%. 2. Head Roll-On revenue was stable. Body Category:

18.91%

s.13.53 crores in Q1 FY23 which is a drop over Q1FY22 by 25.66% but higher than Q1FY21 revenue by 18.91%. 2. Head Roll-On revenue was stable. Body Category: This category grew by 33% in Q1 and our B

33%

1 revenue by 18.91%. 2. Head Roll-On revenue was stable. Body Category: This category grew by 33% in Q1 and our Body roll-on has a long run way of growth as it is only available in 27% of our chem

27%

ory grew by 33% in Q1 and our Body roll-on has a long run way of growth as it is only available in 27% of our chemist outlets that any of the Amrutanjan product is available in. The format along with i

44%

Q4FY22 happened in Q1FY23. As a result, the share of free stock to total billed stock has gone up (44% vs. the usual average of 25-30%) and this led to slower secondary and primary sales. 2. We are e

30%

result, the share of free stock to total billed stock has gone up (44% vs. the usual average of 25-30%) and this led to slower secondary and primary sales. 2. We are eager to catch up with demand in

51%

so in Q4FY23. Women Hygiene business: 1. Comfy business continued to grow with an increase of 51% this Q1 versus the same period last year. A comparison of Q1 results of last 7 years is given i

rs 57.67

2,291.94 2,546.31 F&B 796.40 1,074.24 349.16 854.02 728.41 789.72 856.15 Others 57.67 26.76 8.93 55.85 35.74 120.70 27.48 7,095.42 7,821.15 4,661.85 4,459.59 3,576.84

The macro picture

1

Head category

1

Body Category

1

Women Hygiene business

1

The macro picture

We have experienced a slowdown in the headache pain balm business during this period when compared to last year. However, our Q1 FY 23 figures happen to be the 2nd highest ever produced by Amrutanjan. We are determined to hit our growth targets for the year by focusing more on the new formats and new categories while growing in new markets We, at Amrutanjan, will always continue our efforts to execute the following plan of action: 1. Continue to build an organisation with diversity of brands. This journey started 10 years ago and is challenging but has yielded results but we have long way to go. 2. Grow new formats in strong markets where balms have reached saturation. 3. Develop to improve our share in weak markets with core products in the balm category. 4. Develop Comfy business across weak and strong markets. 5. Continue to grow Exports, Modern Trade, and E-Com channels which have shown growth in Q1. Q1 of the year usually produces around 15% of annual sales with a lesser absorptio

Head category

1. We have lost revenue of Rs.13.53 crores in Q1 FY23 which is a drop over Q1FY22 by 25.66% but higher than Q1FY21 revenue by 18.91%. 2. Head Roll-On revenue was stable.

Body Category

This category grew by 33% in Q1 and our Body roll-on has a long run way of growth as it is only available in 27% of our chemist outlets that any of the Amrutanjan product is available in. The format along with its unique formula is well accepted by consumers. Electro+ business: 1. Electro+ plus revenue has declined in Q1 because of supply issues. We had planned to commission a new line last year to cater to the growth in demand for this brand. However, the new line from Taiwan did not arrive in time (due to Covid related interruptions) to complete the installation in Q3. This has caused supply issues in Q4 last year and that has further rolled over into Q1 this year. A 1 lot of free samples that were to be shipped in Q4FY22 happened in Q1FY23. As a result, the share of free stock to total billed stock has gone up (44% vs. the usual average of 25-30%) and this led to slower secondary and primary sales. 2. We are eager to catch up with demand in the 2nd Summer that arrives in September a

Women Hygiene business

1. Comfy business continued to grow with an increase of 51% this Q1 versus the same period last year. A comparison of Q1 results of last 7 years is given in the table hereunder. Particulars Revenue from operations 30/06/22 30/06/21 30/06/20 30/06/19 30/06/18 30/06/17 30/06/16 Quarter Ended 7,095.42 7,821.15 4,661.85 4,459.59 3,576.84 3,202.36 3,429.94 Other income 301.25 273.89 204.56 155.47 132.01 130.18 113.59 Total income (I + II) 7,396.67 8,095.04 4,866.41 4,615.06 3,708.85 3,332.54 3,543.53 Expenses (a) Cost of materials consumed (b) Purchases of stock- in-trade (c) Changes in inventories of finished goods and stock-in- trade (d) Employee benefits expense (e) Advertisement and selling expenditure (f) Finance cost (g) Depreciation and amortisation expense 2,673.20 2,663.46 694.79 1,684.04 1,743.37 1,342.52 1,590.01 1,339.60 1,081.01 467.53 829.62 485.22 611.63 278.31 - 513.93 - 364.17 970.79 -72.07 - 430.16 - 414.08 - 327.24 1,210.98 1,225.06 914.47 910.82 803.73 800.03 783.30 989.